157 related articles for article (PubMed ID: 23680002)
1. Co-treatment with arsenic trioxide and ganciclovir reduces tumor volume in a murine xenograft model of nasopharyngeal carcinoma.
Sides MD; Sosulski ML; Luo F; Lin Z; Flemington EK; Lasky JA
Virol J; 2013 May; 10():152. PubMed ID: 23680002
[TBL] [Abstract][Full Text] [Related]
2. Arsenic mediated disruption of promyelocytic leukemia protein nuclear bodies induces ganciclovir susceptibility in Epstein-Barr positive epithelial cells.
Sides MD; Block GJ; Shan B; Esteves KC; Lin Z; Flemington EK; Lasky JA
Virology; 2011 Jul; 416(1-2):86-97. PubMed ID: 21605886
[TBL] [Abstract][Full Text] [Related]
3. Enhanced suppression of tumor growth by concomitant treatment of human lung cancer cells with suberoylanilide hydroxamic acid and arsenic trioxide.
Chien CW; Yao JH; Chang SY; Lee PC; Lee TC
Toxicol Appl Pharmacol; 2011 Nov; 257(1):59-66. PubMed ID: 21889949
[TBL] [Abstract][Full Text] [Related]
4. Combination of bifunctional alkylating agent and arsenic trioxide synergistically suppresses the growth of drug-resistant tumor cells.
Lee PC; Kakadiya R; Su TL; Lee TC
Neoplasia; 2010 May; 12(5):376-87. PubMed ID: 20454509
[TBL] [Abstract][Full Text] [Related]
5. Tumor growth inhibition of metastatic nasopharyngeal carcinoma cell lines by low dose of arsenic trioxide via alteration of cell cycle progression and induction of apoptosis.
Yeh KY; Chang JW; Li YY; Wang CH; Wang HM
Head Neck; 2011 May; 33(5):734-42. PubMed ID: 20737493
[TBL] [Abstract][Full Text] [Related]
6. Increased cellular glutathione and protection by bone marrow stromal cells account for the resistance of non-acute promylocytic leukemia acute myeloid leukemia cells to arsenic trioxide in vivo.
Lee C; Lin Y; Huang M; Lin C; Liu C; Chow J; Liu HE
Leuk Lymphoma; 2006 Mar; 47(3):521-9. PubMed ID: 16396776
[TBL] [Abstract][Full Text] [Related]
7. Combination of arsenic trioxide and chemotherapy in small cell lung cancer.
Zheng CY; Lam SK; Li YY; Fong BM; Mak JC; Ho JC
Lung Cancer; 2013 Nov; 82(2):222-30. PubMed ID: 24041618
[TBL] [Abstract][Full Text] [Related]
8. Combination effects of arsenic trioxide and fibroblast growth factor receptor inhibitor in squamous cell lung carcinoma.
Lam SK; Leung LL; Li YY; Zheng CY; Ho JC
Lung Cancer; 2016 Nov; 101():111-119. PubMed ID: 27794399
[TBL] [Abstract][Full Text] [Related]
9. Long-circulating liposome-encapsulated ganciclovir enhances the efficacy of HSV-TK suicide gene therapy.
Kajiwara E; Kawano K; Hattori Y; Fukushima M; Hayashi K; Maitani Y
J Control Release; 2007 Jul; 120(1-2):104-10. PubMed ID: 17509714
[TBL] [Abstract][Full Text] [Related]
10. Synergistic therapeutic effect of arsenic trioxide and radiotherapy in BALB/C nude mice bearing nasopharyngeal carcinoma xenografts.
Xie LX; Lin XH; Li DR; Chen JY; Hong CQ; Du CW
Exp Oncol; 2007 Mar; 29(1):45-8. PubMed ID: 17431388
[TBL] [Abstract][Full Text] [Related]
11. SurvivinT34A increases the therapeutic efficacy of arsenic trioxide in mouse hepatocellular carcinoma models.
Huang A; Yue D; Liao D; Cheng L; Ma J; Wei Y; Tong A; Cheng P
Oncol Rep; 2016 Dec; 36(6):3283-3290. PubMed ID: 27748945
[TBL] [Abstract][Full Text] [Related]
12. Dihydroartemisinin Sensitizes Human Lung Adenocarcinoma A549 Cells to Arsenic Trioxide via Apoptosis.
Chen H; Gu S; Dai H; Li X; Zhang Z
Biol Trace Elem Res; 2017 Oct; 179(2):203-212. PubMed ID: 28261759
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of class I histone deacetylases by romidepsin potently induces Epstein-Barr virus lytic cycle and mediates enhanced cell death with ganciclovir.
Hui KF; Cheung AK; Choi CK; Yeung PL; Middeldorp JM; Lung ML; Tsao SW; Chiang AK
Int J Cancer; 2016 Jan; 138(1):125-36. PubMed ID: 26205347
[TBL] [Abstract][Full Text] [Related]
14. E2F1 downregulation by arsenic trioxide in lung adenocarcinoma.
Lam SK; Li YY; Zheng CY; Leung LL; Ho JC
Int J Oncol; 2014 Nov; 45(5):2033-43. PubMed ID: 25174355
[TBL] [Abstract][Full Text] [Related]
15. Acute promyelocytic leukemia: recent advances in therapy and molecular basis of response to arsenic therapies.
Chou WC; Dang CV
Curr Opin Hematol; 2005 Jan; 12(1):1-6. PubMed ID: 15604884
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of arsenic trioxide on retinoblastoma: cell differentiation and apoptosis depending on arsenic trioxide concentration.
Kim JH; Kim JH; Yu YS; Kim DH; Kim CJ; Kim KW
Invest Ophthalmol Vis Sci; 2009 Apr; 50(4):1819-23. PubMed ID: 19060284
[TBL] [Abstract][Full Text] [Related]
17. Arsenic trioxide cooperates with all trans retinoic acid to enhance mitogen-activated protein kinase activation and differentiation in PML-RARalpha negative human myeloblastic leukemia cells.
Nayak S; Shen M; Bunaciu RP; Bloom SE; Varner JD; Yen A
Leuk Lymphoma; 2010 Sep; 51(9):1734-47. PubMed ID: 20615082
[TBL] [Abstract][Full Text] [Related]
18. The growth-inhibitory and apoptosis-inducing effect of deferoxamine combined with arsenic trioxide on HL-60 xenografts in nude mice.
Yu R; Wang D; Ren X; Zeng L; Liu Y
Leuk Res; 2014 Sep; 38(9):1085-90. PubMed ID: 24908354
[TBL] [Abstract][Full Text] [Related]
19. Promyelocytic leukemia protein induces arsenic trioxide resistance through regulation of aldehyde dehydrogenase 3 family member A1 in hepatocellular carcinoma.
Zhang X; Yang XR; Sun C; Hu B; Sun YF; Huang XW; Wang Z; He YF; Zeng HY; Qiu SJ; Cao Y; Fan J; Zhou J
Cancer Lett; 2015 Sep; 366(1):112-22. PubMed ID: 26118777
[TBL] [Abstract][Full Text] [Related]
20. Dose-adjusted arsenic trioxide for acute promyelocytic leukaemia in chronic renal failure.
Firkin F; Roncolato F; Ho WK
Eur J Haematol; 2015 Oct; 95(4):331-5. PubMed ID: 25600167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
